Nkarta, Inc. Cash and Restricted Cash
Nkarta, Inc. (NKTX) had Cash and Restricted Cash of $27.70 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-10
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $27.70M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $30.10M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $42.38M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $62.86M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $27.70M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $30.10M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $42.38M 10-K · filed 2026-03-25 | |
| 2025-09-30 | $62.86M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $56.16M 10-Q · filed 2026-08-10 | |
| 2025-03-31 | $55.34M 10-Q · filed 2026-05-12 | |
| 2024-12-31 | $30.62M 10-K · filed 2026-03-25 | |
| 2024-09-30 | $59.70M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $123.14M 10-Q · filed 2025-08-12 | |
| 2024-03-31 | $253.03M 10-Q · filed 2025-05-14 | |
| 2023-12-31 | $33.78M 10-K · filed 2025-03-26 | |
| 2023-09-30 | $41.01M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $31.86M 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $56.41M 10-Q · filed 2024-05-09 | |
| 2022-12-31 | $40.24M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $42.40M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $133.74M 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $43.71M 10-Q · filed 2023-05-11 | |
| 2021-12-31 | $62.91M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $98.32M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $24.87M 10-Q · filed 2022-08-11 | |
| 2021-03-31 | $63.02M 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $97.11M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $188.98M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $18.16M 10-Q · filed 2021-08-12 | $18.16M 10-Q · filed 2020-08-20 |
| 2020-03-31 | $16.78M 10-Q · filed 2021-05-13 | |
| 2019-12-31 | $20.88M 10-K · filed 2021-03-25 | |
| 2019-09-30 | $39.36M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $6.18M 10-Q · filed 2020-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |